Guidance Eases Use of PERs in Basic Clinical Research

International Pharmaceutical Regulatory Monitor
A A
The Canadian government has released a draft guidance aimed at streamlining the approval process for basic clinical trials using positron-emitting radiopharmaceuticals, or PERs.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00